The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...

Swedish biotech OncoZenge (Nasdaq: ONCOZ) has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge ...

US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of ...

A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.

Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman.

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) ...